Takeda keeps ticking over as 'pivotal milestones' loom ahead

4 February 2021

Japanese drugmaker Takeda (TYO: 4502) has reported revenue for its first three quarters of the financial year that slipped below the previous year’s levels, but profits that soared.

Takeda’s financial year runs from April to March, and revenue for the nine months from April was 2,427.5 billion yen ($23.05 billion), a decrease of 3.6%, while operating profit rose by nearly 121% to 358.7 billion yen.

"Our third-quarter results demonstrate the resilience of our business modelThe company held its full-year operating profit forecast steady at 434 billion yen, where Refinitiv analysts had predicted 512.5 billion yen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK